EVGEN PHARMA PLC

AGM Presentation

16 July 2020

Disclaimer

This document has been prepared by, and is the sole responsibility of Evgen Pharma plc (the "Company" or "Evgen") which trades on the AIM market of the London Stock Exchange under ticker EVG.

By attending this presentation and/or reviewing the slides, you agree to be bound by the following conditions. Please note that the information in this presentation has yet to be announced or otherwise made public and some or all of the information in this presentation or any discussion surrounding the presentation may constitute inside information relating to the securities of the Company within the meaning of the insider dealing provisions of the Criminal Justice Act 1993 and/or of the Market Abuse Regulation (Regulation 596/2014). By accepting this document the recipient agrees to comply with its obligations under the Market Abuse Regulation, including by not making use of any of inside information for the purpose of dealing, or of counselling or procuring any other person to deal, in the securities of the Company. The information and opinions contained in this presentation have not been independently verified, are provided as at the date hereof and are subject to amendment, revision and completion without notice. No person is under any obligation to update or keep current the information contained in this presentation. No representation, warranty or undertaking, express or implied, is made by the Company, its advisers or representatives, or their respective officers, employees or agents as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reasonableness of the information or the opinions contained herein. The Company, its advisers or representatives, or their respective officers, employees and agents expressly disclaim any and all liability which may be based on this and any errors therein or omissions therefrom.

This document is not an admission document or a prospectus. This document does not constitute or form any part of any offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for, any shares in the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract therefor. This documents has not been authorised or approved for the purposes of section 21 of the Financial Services and Markets Act 2000 and accordingly it is a communication made only to persons who (a) are persons in Member States of the European Economic Area who are qualified investors (within the meaning of article 2(1)(e) of the EU Prospectus Directive (which means Directive 2003/71/EC as amended, and includes the 2010 PD Amending Directive (Directive 2010/73/EU) to the extent implemented in the relevant Member State) (the "Prospectus Directive") ("Qualified Investors"); and in the United Kingdom, are Qualified Investors and who (i) fall within one or more of the exemptions from section 21 of FSMA contained in articles 19, 48, 49, 50 or 50A of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (which includes persons who are authorised or exempt persons within the meaning of FSMA, certain other investment professionals, certified high net worth individuals, high net worth companies, unincorporated associations or partnerships and the trustees of high value trusts and sophisticated investors) and/or (ii) are persons who are otherwise permitted by law to receive it ("Relevant Persons"). Any investment or investment activity to which this document relates is only available to Relevant Persons. Persons of any other description, including those who do not have professional experience in matters relating to investments, should not rely on this document or act on its contents for any purpose whatsoever and should return it to the Company immediately.

If you are in any doubt about the contents of this document, you should consult a person authorised under the Financial Services and Markets Act 2000 who specialises in advising on the acquisition of shares and securities of unlisted companies. You should be aware that an investment in the Company involves a high degree of risk and investors should be aware of such risks and should rely on their own examination of the Company and make the decision to invest only after careful consideration and, if appropriate, consultation with an independent financial adviser. Any investment or investment activity to which this document relates is only available to Relevant Persons. Persons of any other description should not rely on this document or act on its contents for any purpose whatsoever and should return it to the Company immediately.

The distribution of this presentation in certain jurisdictions may be restricted by law, and persons into whose possession this presentation comes should inform themselves about, and observe, any such restrictions. Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been verified by the Company or any other person. Accordingly no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation and no reliance should be placed on such information or opinions. None of the Company, or any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation. No part of this presentation, or the fact of its distribution, should form the basis of or be relied upon in connection with any contract or commitment or investment decision whatsoever.

Recipients of this presentation are not to construe its contents, or any prior or subsequent communications from or with the Company or its representatives as investment, legal or tax advice. In addition, this presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of the Company or any transaction to be entered into by any member of the Evgen group. No undertaking, representation or warranty, express or implied, is given by the Company, any member of the Evgen group, or any of their respective current or proposed directors, officers, partners, employees, secondees, agents or advisers or any other person as to the accuracy or completeness of the information or as to the opinions contained in this document and no liability is accepted for any such information or opinions. Further, the information in this presentation is not complete and may be changed. Recipients of this presentation should each make their own independent evaluation of the information and of the relevance and adequacy of the information in this document and should make such other investigations as they deem necessary.

This presentation may contain forward-looking statements that reflect the Company's current views and expectations regarding future events. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "envisages", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "could", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward looking statements. These forward-looking statements include matters that are not historical facts and speak only as of the date of this document. They appear in a number of places throughout this document and include statements regarding the Company and the directors, and the directors' current intentions, beliefs or expectations concerning, amongst other things, to management's strategic vision, aims and objectives, the conduct of clinical trials, the filing dates for product licence applications and the anticipated launch of specified products in various markets, the Company's ability to find partners for the development and commercialisation of its products as well as the terms for such partnerships, anticipated levels of demand for existing products and products in development, the effect of competition, anticipated efficiencies, trends in results of operations, margins, the overall pharmaceutical market and exchange rates, are all forward looking in nature.

The presentation is confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by its recipients to any other person for any purpose, other than with the consent of the Company. By accepting receipt of, attending any presentation or delivery of or electronically accessing the presentation, you undertake to keep this presentation and the information contained herein confidential and not to forward the presentation to any other person, or to reproduce or publish the presentation, in whole or in part, for any purpose.

Evgen is a clinical stage drug development company with impressive Phase II efficacy data

- Focused on the development of a new class of pharmaceuticals - based on the bioactive compound sulforaphane
- Sulforaphane targets the STAT3 and Nrf2 pathways – of significance in oncology, inflammatory and fibrotic disease
- Platform technology - Sulforadex®
- Strong data from Phase II trial of lead product in metastatic breast cancer (mBC)
- Strong IP covering composition, manufacturing and novel derivatives
- Business model looks to establish clinical proof of concept and partner post-Phase II
- £4m cash at 31 March 2020 funds Company to Q2/Q3 2021
- Covid-19/ARDS trial to commence in Q3/2020

evgen pharma

Current status

- Strong data from Phase II trial of SFX-01 in metastatic breast cancer (mBC)
  - Tumour shrinkage in difficult to treat patient population
  - Five patients received SFX-01 treatment for over one year with no tumour progression
  - Physicians have agreed to support follow-on trial
- Results from mBC and Subarachnoid Haemorrhage trials show SFX-01 is well tolerated with no safety concerns in >100 patients
- April 2019 fundraise being invested in market-ready tablet formulation and extended toxicology
- Incoming academic interest in using SFX-01 in clinical studies - Covid-19 study proceeding and three 3 further MoUs signed
- CEO search well-advanced

evgen pharma

STAR trial (SFX-01 **T**reatment for **A**cute **Respiratory** Infections)

- Randomised Phase II/III trial sponsored by the University of Dundee
- Funded by LifeArc after competitive application process
- 300 patients with confirmed or suspected COVID-19; 50:50 active vs. placebo
- Evaluating if SFX-01 can reduce the severity, or prevent the onset of, acute respiratory distress syndrome ("ARDS")
- Hypothesis is activation of Nrf2 pathway by SFX-01 reduces lung inflammation and oxidative stress
- Patient recruitment commencing in Q3/2020, read-out H2 2021

evgen pharma

Evgen is the only company with a sulforaphane-based medicine in the clinic

- Pure sulforaphane is a liquid that requires storage at minus 20°C to maintain stability, and therefore clinical trials have been precluded
- Sulforadex® technology enables scalable manufacturing of synthetic sulforaphane stabilised in solid-form complex
- Lead product, SFX-01, is a patented complex of synthetic sulforaphane and α-cyclodextrin
- Broad IP relating to novel composition, process and new analogues







SFX-01

The significance of the Nrf2 & STAT3 pathways

evgen pharma

A compound that targets **BOTH** Nrf2 and STAT3 offers unique positioning

- Electrophilic compounds that bind to cysteine revenues can bind to target Nrf2 and STAT3 e.g. sulforaphane and bardoxolone
- The chemistry behind the MoA is thus common to both targets (and others) – allosteric regulation by cysteine "reversible covalent" binding



[1] S3I-201, a selective STAT3 inhibitor, restores neuroimmune function through upregulation of Treg signalling in autistic BTBR T^{+} $Itpr3^{tf}$/J mice (2018);
Nrf2 activator, sulforaphane ameliorates autism-like symptoms through suppression of Th17 related signalling and rectification of oxidant-antioxidant imbalance in periphery and brain of BTBR T+tf/J mice (2019)

The opportunity in metastatic breast cancer

What is the opportunity ?

- ER+ breast cancer is the most prevalent breast cancer sub-type (70%)
- Metastatic breast cancer is incurable with 5-year survival rates of 22%
- Patients become resistant to all drugs
- SFX-01 is being developed to prevent and/or reverse resistance
- Our data on SFX-01 shows prevention of metastases by the STAT3 pathway
- And our recent clinical trial was life changing for some patients

evgen pharma

SFX-01 can be life-changing

- Diagnosed age 40 ER+ Her2- early BC
- Received surgery, chemotherapy and tamoxifen
- After 5 years diagnosed with pleural nodules
- Enrolled into STEM trial May 2017 – tamoxifen + SFX-01
- Objective response to treatment, very well tolerated, able to continue her life caring for her 2 young children and husband with head and neck cancer
- Entered the extended use programme and had Stable Disease for a total of 448 days, including tumour shrinkage of 63% from baseline



5 patients remained progression free after 1 year of treatment with SFX-01 + ET

STEM showed that SFX-01 shrinks tumours and halts tumour growth

- SFX-01 added to tamoxifen or fulvestrant caused tumour shrinkage



- SFX-01 added to endocrine therapy caused tumour stabilisation



Note that patients had already progressed on their current therapy and remained on this, with SFX-01 added on top

Current and planned work programme

- All preclinical breast data published in high impact journal in June 2020
- Extensive review of clinical pathway to approval close to completion
- Supplementary preclinical work required to confirm CDK4/6i “resistance-breaking” hypothesis
- New “commercial ready” solid tablet formulation to be completed in H3 2020
- Non-dilutive capital e.g. partnering to fund the next trial(s)
- Targeting CTA/IND in H1 2021 with first patient first dose in Q2/Q3 2021

Broadening the clinical pipeline through investigator-led trials

evgen pharma

Potential Investigator-Led Clinical Collaborations

NHS
Guy's and St Thomas'
NHS Foundation Trust

"We are working with patient groups to plan a grant application for a Phase II clinical trial programme on **SFX-01 in children with ASD,** hoping to recruit from a consortium of UK hospitals. Our interest, and that of the parents of some children with ASD, was first triggered when a small clinical study showed that sulforaphane helped improve quality of life in autistic young people. Our end goal is improving the range of treatment options available for autistic young people, in order to improve quality of life and independence." **Dr Michael Absoud, a consultant in paediatric neurodisability**

UNIVERSITY OF DUNDEE

"We are delighted that Evgen will support our plans to undertake a clinical trial on **SFX-01 in patients with NASH**. Oxidative stress is pivotal to the development of NASH and our research suggests that activation of the Nrf2 pathway, which in turn reduces oxidative stress, can reverse the pathology." **John Dillon, Professor of Hepatology and Gastrenterology, University of Dundee's the School of Medicine**

UNIVERSITY of ROCHESTER

"We are pleased that Evgen will support our plans to undertake a clinical trial on **SFX-01 in patients with CKD**. Increased oxidative stress is a major molecular underpinning of CKD progression and our research suggests that patients with the GSTM1 null allele may particularly benefit from sulforaphane treatment via SFX-01 dosing.'' **Thu Le, Professor of Medicine and Chief of the Division of Nephrology at the University of Rochester Medical Center**

evgen pharma

Autism Spectrum Disorder (ASD)

Guy's and St Thomas' NHS Foundation Trust

- No approved medicines for treating the three core symptoms of autism
- Encouraging clinical data from a small investigator-led placebo-controlled trial of juvenile patients in the US, using sulforaphane derived from botanical sources
- But no opportunity to move this programme through to a regulated ASD drug using the botanical source
- MoU with GSTT to provide SFX-01 for a large Phase II clinical trial in ASD patients (subject to grant funding)
- Option to license the clinical data to enable subsequent development and commercialisation of SFX-01 in ASD
- SFX-01 has the potential to become a first-in-class treatment for the core symptoms of ASD, disrupting the current £3bn ASD market (which includes the use of anti-depressants and anti-psychotics for the treatment of non-core symptoms)

evgen pharma

Metabolic Associated steatohepatitis (MASH)

- Metabolic associated fatty liver disease (“MAFLD”) is now regarded as the most common liver condition in the developed world, affecting up to 30% of the general population
- 10%-20% of those with MAFLD have MASH and 20-30% of MASH patients are at risk of developing cirrhosis and subsequently dying from end-stage liver disease within 20 years
- Professor John Dillon (University of Dundee) showed that activation of the Nrf2 pathway could reverse insulin resistance, suppress hepatic steatosis, and mitigate against MASH and liver fibrosis.
- MoU with the University of Dundee to supply SFX-01 for a potential clinical trial in MASH
- Option to license the clinical data to enable subsequent development/commercialisation of SFX-01 in MASH and liver fibrosis

Next steps and summary

Next steps and summary

- Focus on the strong efficacy data in breast cancer by planning and executing a Phase IIb trial
- Phase II/III trial in ARDS patients commencing shortly
- Reduce risk and increase probability of success by expanding breadth of clinical programmes:
  - Grant-funded, investigator-led clinical trials (no/small cost to Evgen)
  - In indications with a strong mechanistic rationale (four collaborations announced to date in non-cancer indications)
- Seek commercial partnerships based on Phase II results
- Continue to explore other opportunities to monetise our IP assets
- CEO recruitment process well-advanced

Evgen Pharma plc

Correspondence address:
The Colony
Altrincham Road
Wilmslow
Cheshire SK9 4LY

Registered office:
Liverpool Science Park IC2
146 Brownlow Hill
Liverpool L3 5RF

www.evgen.com